



Domestic Pharmaceutical Manufacturers

प्रविष्टि तिथि: 31 JUL 2026 4:37PM by PIB Delhi

As per the Drugs (Prices Control) Amendment Order, 2026 notified by the Department of Pharmaceuticals (DoP) *vide* S.O. 3516 (E) dated 30th June 2026, any existing manufacturer producing the same new drug formulation whose retail price has been notified by NPPA in preceding twelve months is required to follow the same retail price and intimate to NPPA under Form-1A within one month from the date of launch. Form-1A does not mandate registering the production lines or batches by the domestic pharmaceutical manufacturers.

The National Pharmaceuticals Pricing Authority (NPPA) is entrusted with implementation of Drugs Price Control Order issued by the DoP, from time to time. NPPA monitors the prices of scheduled as well as non-scheduled medicines under DPCO, 2013 and takes action against manufacturers found overcharging the consumers, based on the references received from various resources including Price Monitoring and Resource Units (PMRUs), State Drugs Controllers, samples purchased from the open market, reports from market data base, complaints reported through the grievance redressal channels. The suspected cases of overcharging received from above sources are examined and in case a prima facie case of overcharging is made out, action is initiated as per provisions of DPCO, 2013.

During the last four months, NPPA has issued 103 demand notices to manufacturers across the country including Tamil Nadu. Further, NPPA does not maintain state-wise record of overcharging by pharmaceutical companies.

This information was given by Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a written reply in the Lok Sabha today.

PC/PM

(रिलीज आईडी: 2292477) आगंतुक पटल : 458
इस विज्ञप्ति को इन भाषाओं में पढ़ें: Urdu , हिन्दी